In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria

Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee

doi:10.1128/AAC.48.1.352-357.2004

In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria

Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.

Authors

Dongeun Yong¹, Jong Hwa Yum, Kyungwon Lee, Yunsop Chong, Sung Hak Choi, Jae Keol Rhee

Affiliation

¹ Department of Laboratory Medicine, Research Institute of Bacterial Resistance, and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.

Abstract

In vitro activities of DA-7867, a novel oxazolidinone, were compared to those of linezolid and commonly used antimicrobials. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested, </=0.25 micro g/ml, and it was more potent than linezolid.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acetamides / pharmacology
Anti-Infective Agents / pharmacology*
Bacteria, Aerobic / drug effects*
Bacteria, Anaerobic / drug effects*
Bacterial Infections / microbiology*
Bacteroides / drug effects
Drug Resistance, Bacterial
Enterococcus faecalis / drug effects
Enterococcus faecium / drug effects
Gram-Negative Bacteria / drug effects
Linezolid
Methicillin Resistance
Microbial Sensitivity Tests
Oxazolidinones / pharmacology*
Staphylococcus aureus / drug effects
Vancomycin Resistance

Substances

Acetamides
Anti-Infective Agents
DA-7867
Oxazolidinones
Linezolid